Inner Compass Research Institute Position Statement on the May 4th Mental Health & Overmedicalization Summit

Research Institute Statement No. 01-2026-06-05

The MAHA Institute’s recent Mental Health & Overmedicalization Summit and the announcements made by U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr on antidepressant deprescribing reforms are generating widespread discussion.

The Inner Compass Research Institute encourages all stakeholders to watch the full panels and discussions that preceded Secretary Kennedy’s announcements on May 4, 2026. The MAHA Institute Mental Health & Overmedicalization Summit brought together over 20 speakers. These participants represented more than 18 active non-university organizations – including the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Food and Drug Administration (FDA), National Institute of Mental Health (NIMH), the Administration for Children and Families (ACF), and the Assistant Secretary for Health – along with academic researchers, clinicians, non-profit advocates, and leaders of grassroots reform efforts. ICI was represented by its founder and senior research fellows who presented and moderated throughout the event. Presentations featuring current and former patients offered a rich diversity of expertise and perspectives calling for thoughtful, nuanced reform. These voices provide essential context for the policy announcements that followed. 

Opportunities and Next Steps 
 

To date, safe psychiatric drug deprescribing has received little attention in clinical practice and research settings, despite the many tens of millions of Americans taking these medications. This topic must become a standard part of the conversation. A patient cannot make a true choice about starting a psychiatric prescription without being provided information on safe, accessible medication “off-ramps” down the line if that medication is no longer wanted or needed. Prescribers, therapists, patients and family members alike need clear, up-to-date information on existing evidence for tapering protocols, distinguishing withdrawal from relapse, and how to best address withdrawal symptoms. Without a reliable chain from research to clinical practice to public knowledge, fully informed decisions by patients and practitioners remain impossible. 

This moment presents a unique opportunity for advocates, researchers, and clinicians who have long been focused on addressing the unintended consequences of medicalization to work constructively with policymakers.  Secretary Kennedy’s policy announcements create new opportunities to study real-world deprescribing outcomes, develop evidence-based safe tapering guidelines, train prescribers and clinicians, educate the public, and address challenges and implementation barriers. Currently, prescribers have no choice but to attempt deprescribing without reliable information, guidance, or reimbursement. Addressing those gaps is practical and overdue. 

Inner Compass Research Institute encourages Secretary Kennedy to take immediate action in the following areas: 
 

• Funding of independent real-world research on psychotropic side effects, long-term impacts, withdrawal management, deprescribing outcomes, and expanded non-pharmacological interventions.
• Developing guidance on the use of non-pharmacological alternatives as treatment.
• Creating national evidence-based deprescribing and tapering guidelines that reflect nonlinear dose-response relationships, minimize withdrawal effects, and enable individualized care.
• Developing clinician training and reimbursement for evidence-based tapering and deprescribing, with explicit incentives for providers to reduce polypharmacy.
• Encourage multidisciplinary care and treatment review when possible alongside prescribers and informed choice training for all roles of care teams.
• Standardizing written informed consent for initiating, continuing, changing, or discontinuing psychiatric medications, clearly documenting risks, benefits, and alternatives.
• Providing clear, accessible public and clinical guidance that distinguishes withdrawal from relapse and reviews all options for treating a return of symptoms.
• Ensuring that layperson expertise on psychiatric drug deprescribing is included in federal advisory panels, guideline development, and implementation planning.
• Focusing specifically on reducing unnecessary polypharmacy and psychiatric drug exposure in children, adolescents, and foster youth, groups where prescribing has been especially pronounced.
   

Inner Compass Research Institute’s Role and Commitment

Inner Compass Initiative is a 501c3 nonprofit organization that helps people make informed choices about taking and safely tapering off psychiatric drugs while working to shift culture, science, and policy away from medicalized approaches to human suffering. Our Research Institute bridges clinical, research, and layperson expertise to catalyze meaningful changes in mental health practice, policy, and education. We partner with individuals impacted by unnecessary medicalization, researchers, clinicians, professional societies, and federal agencies. We are a nonpartisan organization eager to partner across the political spectrum with those who share in our vision for a mental health system oriented around transparency, integrity, pluralism, and truly informed choice. 

In commitment,
Inner Compass Research Institute 
June 2026